IL17A and psoriasis: In particular, we provide the first evidence for oral efficacy of RORγt inhibition in blocking IL-23-dependent psoriasis-like mouse skin inflammation, and inhibition of antigen-triggered IL-17 production in human skin-homing psoriatic T cells.